These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30478722)

  • 1. Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
    J Thromb Thrombolysis; 2019 Jan; 47(1):155-156. PubMed ID: 30478722
    [No Abstract]   [Full Text] [Related]  

  • 2. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
    Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
    J Thromb Thrombolysis; 2018 Jan; 45(1):106-113. PubMed ID: 29022213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.
    Ohyashiki K; Ito Y; Hori K; Sato K; Makino T; Ohyashiki JH
    Leukemia; 2007 Jul; 21(7):1570-1. PubMed ID: 17392820
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.
    De Stefano V; Rossi E; Za T; Ciminello A; Betti S; Luzzi C; Leone G; Chiusolo P
    Am J Hematol; 2011 Jun; 86(6):526-8. PubMed ID: 21594892
    [No Abstract]   [Full Text] [Related]  

  • 6. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia.
    Trifa AP; Bănescu C; Voina CM; Popa Ș; Török-Vistai T; Bojan AS; Dima D; Zdrenghea M; Fetica B; Vișan S; Tomuleasa C; Pârvu A; Urian L; Pop B; Popov VM; Andreescu M; Popp RA
    Blood Cells Mol Dis; 2018 Nov; 73():45-46. PubMed ID: 30249383
    [No Abstract]   [Full Text] [Related]  

  • 7. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
    Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
    Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
    Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
    Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
    [No Abstract]   [Full Text] [Related]  

  • 10. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia.
    Wong RS; Cheng CK; Chan NP; Cheng SH; Wong WS; Lau KM; Cheng G; Ng MH
    Br J Haematol; 2008 Jun; 141(6):902-4. PubMed ID: 18410451
    [No Abstract]   [Full Text] [Related]  

  • 12. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation.
    Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL
    Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212
    [No Abstract]   [Full Text] [Related]  

  • 13. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
    Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.
    Moreno MJ; Lozano ML; Roldán V; Bellosillo B; García-Barberá N; Rivera J; Navarro-Núñez L; Besses C; Vicente V; Martínez C
    Ann Hematol; 2008 Sep; 87(9):763-5. PubMed ID: 18365193
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.
    Cho YU; Chi HS; Lee EH; Jang S; Park CJ; Seo EJ
    Int J Hematol; 2009 Jan; 89(1):39-44. PubMed ID: 19093167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The V617F mutation of JAK2 is very uncommon in patients with thrombosis.
    Remacha AF; Estivill C; Sarda MP; Mateo J; Souto JC; Canals C; Nomdedéu J; Fontcuberta J
    Haematologica; 2007 Feb; 92(2):285-6. PubMed ID: 17296594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.